DNA甲基转移酶3A(DNMT3A)突变与非小细胞肺癌PD-(L)1阻断疗效
在1539例非小细胞肺癌中,4.7%存在DNMT3A有害突变;DNMT3A突变患者接受PD-(L)1阻断的缓解率41.7% vs 21.5%(P<0.001),无进展生存HR 0.61(P<0.001),总生存HR 0.66(P<0.01),均优于野生型;未接受ICI者OS无差异(HR 0.88,P=0.41)。
要点
- DNMT3A突变在NSCLC中占4.7%,与PD-(L)1阻断后缓解率、PFS和OS改善相关。
- 未接受ICI的晚期NSCLC中,DNMT3A突变对OS无影响(HR 0.88,P=0.41)。
- 克隆性DNMT3A突变仍与免疫治疗结局改善相关,排除克隆性造血干扰。
核心结论
- 体细胞DNMT3A突变可在部分NSCLC中检出,与DNMT3A表达降低和有利免疫表型相关,并预测ICI疗效改善。
研究设计与样本
- 纳入多个独立队列中接受ICI治疗且行全面基因组分析的晚期NSCLC患者,共1539例NSCLC。
- 采用β-二项模型对测序读数计数推断突变克隆性;利用TCGA的NSCLC样本和CCLE的NSCLC细胞系进行转录组分析。
主要发现
- 在1539例NSCLC中,4.7%检出有害DNMT3A突变。
- DNMT3A突变患者接受PD-(L)1阻断的缓解率为41.7% vs 野生型21.5%(P<0.001),PFS的HR 0.61(P<0.001),OS的HR 0.66(P<0.01)。
- 未接受ICI的晚期NSCLC患者中,DNMT3A突变对OS无影响(HR 0.88,P=0.41)。
- 克隆性DNMT3A突变与野生型相比仍与免疫治疗结局改善相关。
- 在携带致病性DNMT3A突变的NSCLC细胞系中,DNMT3A RNA和蛋白表达降低;TCGA中DNMT3A高表达较低表达的NSCLC,其先天和适应性免疫应答通路(包括IFNγ、MHC-II抗原呈递、TNF-α和PD-1信号)表达降低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite significant improvements in overall survival with programmed cell death protein (ligand) 1 [PD-(L)1] inhibition, most patients with metastatic non-small-cell lung cancer (NSCLC) do not respond to immune checkpoint inhibition (ICI). Growing evidence suggests the importance of genomic alterations in modulating anticancer immune response and predicting ICI efficacy. However, the genomic correlates of response to ICI in NSCLC are largely unknown. DESIGN: Patients with advanced NSCLC treated with ICI and comprehensive genomic profiling from multiple independent cohorts were included. Beta-binomial modelling of sequencing read counts was used to infer mutation clonality. NSCLC samples from Cancer Genome Atlas Program (TCGA) and NSCLC cell lines from Cancer Cell Lines Encyclopedia (CCLE) were used for transcriptomic analyses. RESULTS: Among 1539 NSCLCs, we identified deleterious DNA methyltransferase 3A (DNMT3A) mutations in 4.7% of cases. Patients with DNMT3A-mutant NSCLC had improved response rate (41.7% versus 21.5%, P < 0.001), progression-free survival [hazard ratio (HR) 0.61, P < 0.001], and overall survival (HR 0.66, P < 0.01) with PD-(L)1 blockade, compared with DNMT3A wild-type cases. DNMT3A mutations had no impact on OS among patients with advanced NSCLC who did not receive ICI (HR 0.88, P = 0.41). In examining the impact of DNMT3A clonality on immunotherapy outcomes to account for potential clonal hematopoiesis of indeterminate potential contamination, we confirmed that clonal DNMT3A mutations were associated with improved outcomes compared with DNMT3A wild-type cases. In NSCLC cell lines with pathogenic DNMT3A mutations, DNMT3A RNA and protein expression were decreased. In the TCGA, NSCLCs with high versus low DNMT3A expression exhibited lowered expression of pathways involved in innate and adaptive immune response, including interferon-γ (INFγ), major histocompatibility complex (MHC)-II antigen presentation, tumor necrosis factor-α (TNF-α), and PD-1 signaling. CONCLUSION: Somatic DNMT3A mutations can be detected in a fraction of NSCLCs and are associated with a decreased DNMT3A expression and a favorable immunophenotype, and predict improved ICI efficacy.
引用
- Ricciuti B, Scalera S, Wang X, et al. DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer. Ann Oncol. 2025. PMID: 40541864. doi:10.1016/j.annonc.2025.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。